Clinical Trial Update: Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of tremelimumab and durvalumab with gemcitabine/cisplatin for intrahepatic cholangiocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• IMFINZI (DURVALUMAB)
• Platinol (cisplatin)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Georgetown University | Conditions: Borderline Resectable Carcinoma, Biliary Tract Cancer | Phase 2 | Status: WITHDRAWN